Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma

被引：8
|
作者：
Carbone, Antonino [1 ,5 ]
Gloghini, Annunziata [2 ]
Carlo-Stella, Carmelo [3 ,4 ]
机构：
[1] IRCCS, Ist Nazl Tumori, Ctr Riferimento Oncol Aviano, Dept Pathol, Aviano, Italy
[2] Fdn IRCCS, Ist Nazl Tumori, Dept Diagnost Pathol & Lab Med, Milan, Italy
[3] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[4] IRCCS Humanitas Res Hosp, Dept Oncol & Hematol, Milan, Italy
[5] IRCCS, Ist Nazl Tumori, Ctr Riferimento Oncol Aviano, Via F Gallini 2, I-33081 Aviano, Italy
来源：
BLOOD | 2023年 / 141卷 / 18期
关键词：
REED-STERNBERG CELLS; PD-1; BLOCKADE; BRENTUXIMAB VEDOTIN; PHASE-II; T-CELLS; NIVOLUMAB; PEMBROLIZUMAB; RESISTANCE; SURVIVAL; TRANSPLANTATION;
D O I：
10.1182/blood.2022016590
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Classic Hodgkin lymphoma (cHL) is characterized by a tumor microenvironment (TME) containing inflammatory/ immune cells. Follicular lymphoma, mediastinal gray zone lymphoma, and diffuse large B-cell lymphomas may show a TME containing inflammatory/immune cells, but the TMEs are quite different. In B-cell lymphomas and cHL, programmed cell death 1 (PD-1)-PD ligand 1 pathway blockade drugs differ in their effectiveness among patients with refractory/relapsed disease. Further research should explore innovative assays that could reveal which molecules influence sensitivity or resistance to therapy in an individual patient.
引用
收藏
页码：2187 / 2193
页数：7
相关论文
共 50 条
  • [1] Tumour Microenvironment Contribution to Checkpoint Inhibitor Therapy in Classic Hodgkin Lymphoma
    Gloghini, Annunziata
    Carbone, Antonino
    HEMATO, 2024, 5 (02): : 199 - 207
  • [2] Checkpoint blockade therapy resistance in Hodgkin's lymphoma
    Carbone, Antonin
    Gloghini, Annunziata
    LANCET, 2018, 392 (10154): : 1194 - 1196
  • [3] Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
    Merryman, Reid W.
    Armand, Philippe
    Wright, Kyle T.
    Rodig, Scott J.
    BLOOD ADVANCES, 2017, 1 (26) : 2643 - 2654
  • [4] Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
    Carbone, Antonino
    Gloghini, Annunziata
    Pruneri, Giancarlo
    Dolcetti, Riccardo
    CANCER MEDICINE, 2019, 8 (06): : 3012 - 3016
  • [5] Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?
    Phillips, Elizabeth H.
    Illidge, Tim M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (01) : 13 - 14
  • [6] Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
    Carreau, Nicole A.
    Pail, Orrin
    Armand, Philippe
    Merryman, Reid
    Advani, Ranjana H.
    Spinner, Michael A.
    Herrera, Alex
    Chen, Robert
    Tomassetti, Sarah
    Ramchandren, Radhakrishnan
    Hamid, Muhammad S.
    Assouline, Sarit
    Santiago, Raoul
    Wagner-Johnston, Nina
    Paul, Suman
    Svoboda, Jakub
    Bair, Steven
    Barta, Stefan
    Liu, Yang
    Nathan, Sunita
    Karmali, Reem
    Burkart, Madelyn
    Torka, Pallawi
    David, Kevin
    Wei, Catherine
    Lansigan, Frederick
    Emery, Lukas
    Persky, Daniel
    Smith, Sonali
    Godfrey, James
    Chavez, Julio
    Xia, Yuhe
    Troxel, Andrea B.
    Diefenbach, Catherine
    ONCOLOGIST, 2020, 25 (10): : 878 - 885
  • [7] Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classical Hodgkin Lymphoma
    Sanchez-Aguilera, Abel
    Montalban, Carlos
    De la Cueva, Paloma
    Sanchez-Verde, Lydia
    Morente, Manuel M.
    Garcia-Cosio, Monica
    Garcia-Larana, Jose
    Bellas, Carmen
    Provencio, Mariano
    Romagosa, Vicens
    Fernandez de Sevilla, Alberto
    Menarguez, Javier
    Sabin, Pilar
    Mestre, Maria J.
    Mendez, Miguel
    Fresno, Manuel F.
    Nicolas, Concepcion
    Piris, Miguel A.
    Garcia, Juan F.
    CANCER RESEARCH, 2006, 66 (08)
  • [8] Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma
    Sanchez-Aguilera, Abel
    Montalban, Carlos
    de la Cueva, Paloma
    Sanchez-Verde, Lydia
    Morente, Manuel M.
    Garcia-Cosio, Monica
    Garcia-Larana, Jose
    Bellas, Carmen
    Provencio, Mariano
    Romagosa, Vicens
    de Sevilla, Alberto Fernandez
    Menarguez, Javier
    Sabin, Pilar
    Mestre, Maria J.
    Mendez, Miguel
    Fresno, Manuel F.
    Nicolas, Concepcion
    Piris, Miguel A.
    Garcia, Juan F.
    BLOOD, 2006, 108 (02) : 662 - 668
  • [9] Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
    Lin, Adam Yuh
    Schnitter, Joseph Michael
    Gordon, Leo, I
    IMMUNOTARGETS AND THERAPY, 2022, 11 : 1 - 10
  • [10] The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
    Russell, Bonnie L.
    Sooklal, Selisha A.
    Malindisa, Sibusiso T.
    Daka, Lembelani Jonathan
    Ntwasa, Monde
    FRONTIERS IN ONCOLOGY, 2021, 11
12345